Enovis Corporation (NYSE:ENOV) Given Average Rating of “Moderate Buy” by Analysts

Shares of Enovis Corporation (NYSE:ENOV) have been given an average rating of “Moderate Buy” by the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $46.7143.

Several equities analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a report on Wednesday, October 8th. Canaccord Genuity Group decreased their price objective on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. UBS Group reissued a “buy” rating and set a $50.00 target price on shares of Enovis in a research report on Monday, January 5th. Evercore ISI restated an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Finally, Wells Fargo & Company lifted their price objective on Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th.

Enovis Stock Performance

Shares of ENOV opened at $22.69 on Friday. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -0.96 and a beta of 1.52. The company’s fifty day moving average is $26.65 and its 200-day moving average is $28.96. The company has a quick ratio of 1.16, a current ratio of 2.22 and a debt-to-equity ratio of 0.66. Enovis has a 12 month low of $21.00 and a 12 month high of $48.37.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.08. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. The firm had revenue of $548.91 million during the quarter, compared to analysts’ expectations of $538.61 million. During the same period in the prior year, the company posted $0.73 earnings per share. Enovis’s revenue for the quarter was up 8.7% on a year-over-year basis. Enovis has set its FY 2025 guidance at 3.100-3.250 EPS. Equities analysts expect that Enovis will post 2.79 EPS for the current fiscal year.

Insider Buying and Selling

In other Enovis news, insider John Kleckner acquired 2,468 shares of Enovis stock in a transaction dated Tuesday, November 25th. The stock was bought at an average cost of $30.32 per share, with a total value of $74,829.76. Following the completion of the transaction, the insider owned 12,302 shares of the company’s stock, valued at $372,996.64. The trade was a 25.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Daniel A. Pryor sold 999 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The SEC filing for this sale provides additional information. 2.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Enovis

A number of institutional investors have recently added to or reduced their stakes in ENOV. Farther Finance Advisors LLC raised its holdings in Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after acquiring an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in Enovis in the second quarter worth $46,000. SJS Investment Consulting Inc. boosted its stake in Enovis by 30,340.0% during the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after buying an additional 1,517 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Enovis by 353.5% during the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after buying an additional 1,446 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.